miR-29b Inhibits the Malignant Progression of Gallbladder Carcinoma by Regulating Tet Methylcytosine Dioxygenase 3

This study investigated the impact of miR-29b on the proliferative ability and apoptosis of gallbladder cancer (GBC) cells by targeting TET3. The levels of miR-29b were measured using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in GBC tissues and adjacent non-cancerous tissues. The clinical features of GBC patients were analyzed based on miR-29b expression. Overexpression of miR-29b in GBC-SD and NOZ cells was found to significantly reduce proliferation, as assessed by CCK-8 and colony formation assays, and increase apoptosis, as measured by flow cytometry. The regulatory mechanism between miR-29b and its target gene TET3 was confirmed through luciferase assays and rescue experiments. In a GBC mouse model, overexpression of miR-29b in GBC-SD cells suppressed tumor growth and reduced tumor weight. Low expression of miR-29b in GBC tissues was associated with advanced tumor stage, larger tumor size, and poor prognosis. TET3, which was upregulated in GBC tissues, showed an inverse correlation with miR-29b expression. Overexpression of TET3 counteracted the effects of miR-29b on proliferation and apoptosis in GBC cells. In summary, miR-29b inhibits the malignant progression of GBC by regulating TET3 and holds potential as a prognostic marker.